Patrick G. Lepore - 15 Jan 2025 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Reporting relationship: Director
Issuer ticker: VYNE
Reported as of: 15 Jan 2025
Net transaction value: +$43,800
SEC form: 4
Accepted by SEC: 16 Jan 2025, 18:06:19 UTC
Prior SEC filing: 13 Dec 2024
Next SEC filing: 15 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mutya Harsch, as attorney-in-fact for Patrick G. LePore

Key filing fact

Patrick G. Lepore filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 16 Jan 2025.

Key facts

This page summarizes Patrick G. Lepore's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Jan 2025, 18:06.

Change

Previous filing in this sequence was filed on 13 Dec 2024.
Current net transaction value: +$43,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNE transaction

Common Stock

Purchase

Transaction value: $43,800
Shares: +15,000
Change %: +41%
Price: $2.92
Shares after: 51,472
Date: 15 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.8776 to $2.9836, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.